bioAffinity Technologies Announces Notification of Japanese Patent Allowance Covering Noninvasive CyPath® Lung and AI-Built Algorithm
Business Wire•08/10/2026•08:00 ET
1
Key Highlights
- ➤Japanese patent allowance covers CyPath Lung’s AI-built lung cancer prediction algorithm
- ➤22 awarded U.S. and foreign patents, with 36 applications pending
- ➤Japanese patent would be CyPath Lung’s first awarded in Japan
- ➤Asian patent protection reaches five awards, including China and Hong Kong
- ➤CyPath Lung trial showed 92% sensitivity and 99% negative predictive value
Expert Statements
Maria Zannes, President and CEO of bioAffinity Technologies
“The Japanese patent for the CyPath Lung test strengthens and expands the Company’s intellectual property protection in the Asian market by protecting our innovative, noninvasive test for early-stage lung cancer. We anticipate patents in additional geographic regions will follow.”
Maria Zannes, President and CEO of bioAffinity Technologies
“Lung cancer is the deadliest cancer worldwide. We believe CyPath Lung has the potential to improve the outcome for lung cancer patients around the globe through earlier detection when treatment options are better. Strong intellectual property protection for the CyPath Lung test benefits not only patients and their physicians, but also our shareholders and our Company. Our scientific team continues research and development on diagnostics that will open new markets for bioAffinity Technologies.”
bioAffinity Technologies Announces Notification of Japanese Patent Allowance Covering Noninvasive CyPath® Lung and AI-Built Algorithm
Company’s expanding intellectual property portfolio strengthens protection for its early lung cancer diagnostic in Asia
Get started
Create a free account to read the full story.